SEC Form 4 · accession 0001127602-17-009486
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. · CRL
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Robert J Bertolini
Director
Period of report
Mar 1, 2017
Accepted (ET)
Mar 2, 2017 · 11:36 am EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001100682
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Mar 1, 2017 | S | 100 | $87.78 | D | 26,785 | D | |
| Common Stock | Mar 1, 2017 | S | 200 | $87.91 | D | 26,585 | D | |
| Common Stock | Mar 1, 2017 | S | 400 | $87.92 | D | 26,185 | D | |
| Common Stock | Mar 1, 2017 | S | 200 | $87.93 | D | 25,985 | D | |
| Common Stock | Mar 1, 2017 | S | 500 | $87.94 | D | 25,485 | D | |
| Common Stock | Mar 1, 2017 | S | 100 | $87.945 | D | 25,385 | D | |
| Common Stock | Mar 1, 2017 | S | 100 | $87.95 | D | 25,285 | D | |
| Common Stock | Mar 1, 2017 | S | 200 | $87.96 | D | 25,085 | D | |
| Common Stock | Mar 1, 2017 | S | 743 | $87.98 | D | 24,342 | D | |
| Common Stock | Mar 1, 2017 | S | 100 | $87.99 | D | 24,242 | D | |
| Common Stock | Mar 1, 2017 | S | 2,726 | $88.00 | D | 21,516 | D | |
| Common Stock | Mar 1, 2017 | S | 100 | $88.02 | D | 21,416 | D | |
| Common Stock | Mar 1, 2017 | S | 300 | $88.03 | D | 21,116 | D | |
| Common Stock | Mar 1, 2017 | S | 165 | $88.06 | D | 20,951 | D | |
| Common Stock | Mar 1, 2017 | S | 100 | $88.08 | D | 20,851 | D | |
| Common Stock | Mar 1, 2017 | S | 100 | $88.12 | D | 20,751 | D | |
| Common Stock | Mar 1, 2017 | S | 200 | $88.13 | D | 20,551 | D | |
| Common Stock | Mar 1, 2017 | S | 1 | $88.17 | D | 20,550 | D | |
| Common Stock | Mar 1, 2017 | S | 100 | $88.21 | D | 20,450 | D | |
| Common Stock | Mar 1, 2017 | S | 100 | $88.23 | D | 20,350 | D | |
| Common Stock | Mar 1, 2017 | S | 100 | $88.27 | D | 20,250 | D | |
| Common Stock | Mar 1, 2017 | S | 100 | $88.34 | D | 20,150 | D |
Table II — derivative securities
No Table II lines on this filing.